PRESTO-ENGINEERING
16.1.2023 09:01:40 CET | Business Wire | Press release
Presto Engineering, the recognized microelectronics expert from ASIC design to semiconductor production services, announces a strengthening of its leadership to support its aggressive strategic plan of future growth. Cédric Mayor, VP Global Strategy & Corporate Development, is appointed Chief Executive Officer (CEO) of the company. Previous CEO, and company founder, Michel Villemain, is appointed Executive Chairman, primarily focusing on strategic and corporate development. The change is effective January 11, 2023, and is the result of a year-long transition process initiated by the company’s leadership.
“As a member of the core management team of Presto, Cédric has played a key role in the development of the company over the years, and I am glad that he is stepping up to CEO,” said Thomas Fort, Chairman of the company’s Supervisory Board. “I would also like to thank Michel Villemain for his vision and strong leadership over the years, and I am delighted that Michel is staying on as Executive Chairman. I am looking forward to working with both Cédric and Michel in their new roles.”
“Presto Engineering has come a long way since 2006, when we started it with Frank Sauk in California,” said Michel Villemain. “In the past 16 years, we have established a market leader and created the foundation for further expansion. I wish Cédric all the best in driving the company forward, after all we have done together for Presto since 2009. I want to thank our team—and all who have contributed to Presto’s achievements over the years—for their dedication and efforts and our shareholders for their confidence and support. I look forward to participating in our continued success in this more strategic role.”
“I feel honored to be appointed as the next CEO of Presto Engineering, and together with our extremely talented colleagues, will continue to help our customers create their products through semiconductor innovations and passion,” said Cédric Mayor, incoming CEO of Presto Engineering. “I wish to thank Michel Villemain for this amazing 13-year journey we shared together while continuing working with him in his new role, as well as to the Supervisory Board for their confidence. I look forward to shaping the next chapter of Presto Engineering, while empowering our team to deliver outstanding service and support that exceeds our customers’ expectations.”
Cédric Mayor has more than 23 years of experience in the semiconductor business, which includes 13 years at Presto Engineering across various executive management positions. Cédric has held several technical and executive management roles at NXP Semiconductors, from process release to front-end and back-end of line migration, as part of the asset light company vision. Cédric started his career with SOISIC (a start-up acquired by Arm) as lead architect of silicon embedded memory and compilers. Cédric graduated from Ecole Centrale Marseille in France; he holds an MS in Physics & Electrical Engineering, with several patents and papers in the field.
About Presto Engineering
Presto Engineering provides ASIC design and outsourced operations for semiconductor and IoT device companies, helping its customers minimize overhead, reduce risk, and accelerate time-to-market. The company is a recognized expert in the development of industrial solutions for RF, analog, mixed-signal, and secured applications―from design, tape-out, to delivery of finished goods. Presto’s proprietary, highly secure manufacturing and provisioning solution, coupled with extensive back-end expertise, gives its customers a competitive advantage. The company offers a global, flexible, dedicated framework, with headquarters in Meyreuil, France, and operations across Europe, North America, and Asia. For more information, visit: www.presto-eng.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005105/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom